Tirzepatide (Tirzepatide (Dual GIP/GLP-1 Receptor Agonist))
A dual GIP and GLP-1 receptor agonist approved as Mounjaro/Zepbound. Achieves up to 22.5% body weight loss, the highest of approved therapies.
How it works
Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure.
Key facts
- Molecular weight: 4,814 Da
- Half-life: 5 days (120 hours)
- Bioavailability: High (SubQ ~80%)
- Storage: Refrigerated 2-8°C. Single-use pens.
Dosing overview
- Typical dose: 2.5 mg → titrate up to 15 mg
- Frequency: Once weekly
- Duration: Ongoing (chronic)
- Route: Subcutaneous injection
Protocol notes
- Start at 2.5 mg once weekly for 4 weeks (tolerance dose).
- Increase by 2.5 mg every 4 weeks as tolerated: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg.
- Settle at the lowest effective dose for appetite/weight control.
- Keep to one consistent weekday.
Reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Possible side effects
- Nausea (most common)
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Injection site reactions
Research
- SURMOUNT-1: Tirzepatide for weight management in obesity (2022): Participants on 15mg lost 22.5% of body weight vs 2.4% placebo over 72 weeks.
- SURPASS-4: Tirzepatide vs insulin glargine in T2DM (2022): Tirzepatide demonstrated superior HbA1c reduction with 10-12kg weight loss advantage.
Compare Tirzepatide
Community discussions about Tirzepatide
- Limited-Time Promotion - 0 comments
- Factory Direct With Full After‑Sales Protection - 3 comments
- China Peptide Source Factory - 3 comments
- Semaglutide plateau after 12 weeks, anyone else hit this wall? - 3 comments
- Anyone running KLOW with low dose tirzepatide? - 6 comments
- Ask the community about Tirzepatide
Research and educational reference only. Not medical advice.